Our findings suggest that the NSCLC patients carrying the CCDC6 fusions, beside the kinase inhibitors, might also benefit of the inclusion of PARPi in order to prevent cancer cell resistance. The gene discussed is CCDC6; the disease is non-small cell lung carcinoma.